Composition for preventing or treating cancer, containing IL-2 surface expression-extracellular vesicles as active ingredient
The present invention relates to a composition for preventing or treating cancer, the composition containing IL-2 surface expression-extracellular vesicles as an active ingredient. According to the present invention, immune cells, in which useful cytokines have been expressed on the cell surface, and extracellular vesicles, preferably small extracellular vesicles (sEV), which are derived from the immune cells and have useful cytokines expressed on the surface were prepared using a lentiviral vector containing a cytokine-linker-a PDGF receptor transmembrane domain, and it was found that the extracellular vesicles increased proliferation and activity of cytotoxic T cells thereby increasing anti-cancer immune efficacy. Thus, the extracellular vesicles having the efficacy can be usefully utilized as a pharmaceutical composition for preventing or treating cancer, a pharmaceutical composition for co-administration with an anticancer drug, or a composition for delivering a drug or a physiologically active material.
1 . A method of treating melanoma having increased programmed death ligand 1 (PD-L1) expression, comprising:
administering to a subject a pharmaceutical composition comprising, as an active ingredient, an extracellular vesicle comprising a fusion protein including IL-2, linker, and a transmembrane domain of platelet-derived growth factor (PDGF) receptor, wherein the fusion protein is expressed on a surface of the extracellular vesicle.
2 . The method of claim 1 , wherein the composition is co-administered with an anticancer drug.
3 . A method of treating melanoma having increased programmed death ligand 1 (PD-L1) expression, comprising:
administering to a subject a pharmaceutical composition comprising, as active ingredient, an extracellular vesicle comprising a fusion protein including IL-2, linker, and a transmembrane domain of platelet-derived growth factor (PDGF) receptor, wherein the fusion protein is expressed on a surface of the extracellular vesicle, and cisplatin.